Targeted Radiation for Cancer: Lori Lyons-Williams on The Long Run

Today’s guest on The Long Run is Lori Lyons-Williams.

Lori Lyons-Williams, CEO, Abdera Therapeutics

She’s the CEO of Menlo Park, Calif. and Vancouver, BC-based Abdera Therapeutics.

Abdera is a startup developing targeted antibody drugs loaded with potent microdoses of radiation to give them extra tumor-killing punch. This type of treatment modality has been around for decades. Targeted radiation hasn’t lived up to the full potential scientists have long imagined, but Abdera is part of an emerging crop of new companies that are working through some the classic technical challenges. Abdera announced a $142 million combined Series A and B financing, which I wrote about at the time for subscribers of Timmerman Report.

In this conversation, we talk about Lori’s early career experiences in sales and marketing, a couple key turning points for her growth, the opportunity she sees for targeted radiopharmaceuticals as an emerging class of therapy – especially for tough-to-treat solid tumors. Toward the end, she has some advice for women in biotech.

Now, before we get started, a word from the sponsor.

In the 10 years it takes for a new biopharmaceutical or device to be developed, more than 304 million people die waiting for treatment. Don’t settle for slow, ineffective patient engagement — not when people are counting on you! Elligo Health Research gives you immediate access to known, diverse patients so you can quickly get your product to the people who need it. Go to ElligoHealthResearch.com and get the patients you need, right now. Because they’ve waited long enough.

Learn more at Elligohealthresearch.com

Now, please join me and Lori Lyons-Williams on The Long Run.